(S)-5-(7-(2-((5-chloro-2-(2,4-dimethylpiperazin-1-yl)pyridin-4-yl)amino)-2-oxoethyl)-2,3-dimethyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)-3,4-difluoro-2-hydroxybenzamide

ID: ALA5290428

Chembl Id: CHEMBL5290428

Max Phase: Preclinical

Molecular Formula: C28H29ClF2N8O4

Molecular Weight: 615.04

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1nc2c(c(-c3cc(C(N)=O)c(O)c(F)c3F)cn2CC(=O)Nc2cc(N3CCN(C)C[C@@H]3C)ncc2Cl)c(=O)n1C

Standard InChI:  InChI=1S/C28H29ClF2N8O4/c1-13-10-36(3)5-6-39(13)20-8-19(18(29)9-33-20)35-21(40)12-38-11-17(22-27(38)34-14(2)37(4)28(22)43)15-7-16(26(32)42)25(41)24(31)23(15)30/h7-9,11,13,41H,5-6,10,12H2,1-4H3,(H2,32,42)(H,33,35,40)/t13-/m0/s1

Standard InChI Key:  JJACRWNCVAHDPS-ZDUSSCGKSA-N

Alternative Forms

  1. Parent:

    ALA5290428

    ---

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KARPAS-422 (454 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 615.04Molecular Weight (Monoisotopic): 614.1968AlogP: 2.62#Rotatable Bonds: 6
Polar Surface Area: 151.61Molecular Species: ACIDHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 6.31CX Basic pKa: 7.70CX LogP: 1.66CX LogD: 1.62
Aromatic Rings: 4Heavy Atoms: 43QED Weighted: 0.30Np Likeness Score: -1.39

References

1. Mamai A, Chau AM, Wilson BJ, Watson ID, Joseph BB, Subramanian PR, Morshed MM, Morin JA, Prakesch MA, Lu T, Connolly P, Kuntz DA, Pomroy NC, Poda G, Nguyen K, Marcellus R, Strathdee G, Theriault B, Subramaniam R, Mohammed M, Abibi A, Chan M, Winston J, Kiyota T, Undzys E, Aman A, Austin N, Du Jardin M, Packman K, Phillippar U, Attar R, Edwards J, O'Meara J, Uehling DE, Al-Awar R, Privé GG, Isaac MB..  (2023)  Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.,  14  (2.0): [PMID:36793435] [10.1021/acsmedchemlett.2c00502]

Source